These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31564802)

  • 1. An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
    Liang X; Li H; Coussy F; Callens C; Lerebours F
    Chin J Cancer Res; 2019 Aug; 31(4):586-600. PubMed ID: 31564802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
    Hein A; Lambrechts D; von Minckwitz G; Häberle L; Eidtmann H; Tesch H; Untch M; Hilfrich J; Schem C; Rezai M; Gerber B; Dan Costa S; Blohmer JU; Schwedler K; Kittel K; Fehm T; Kunz G; Beckmann MW; Ekici AB; Hanusch C; Huober J; Liedtke C; Mau C; Moisse M; Müller V; Nekljudova V; Peuteman G; Rack B; Rübner M; Van Brussel T; Wang L; Weinshilboum RM; Loibl S; Fasching PA
    Int J Cancer; 2015 Dec; 137(12):2981-8. PubMed ID: 26100253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
    Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
    Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
    Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
    Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of response for the antiangiogenic agent bevacizumab.
    Lambrechts D; Lenz HJ; de Haas S; Carmeliet P; Scherer SJ
    J Clin Oncol; 2013 Mar; 31(9):1219-30. PubMed ID: 23401453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.
    Affronti ML; Jackman JG; McSherry F; Herndon JE; Massey EC; Lipp E; Desjardins A; Friedman HS; Vlahovic G; Vredenburgh J; Peters KB
    Oncologist; 2018 Aug; 23(8):889-e98. PubMed ID: 29666296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    Martín M; Loibl S; Hyslop T; De la Haba-Rodríguez J; Aktas B; Cirrincione CT; Mehta K; Barry WT; Morales S; Carey LA; Garcia-Saenz JA; Partridge A; Martinez-Jañez N; Hahn O; Winer E; Guerrero-Zotano A; Hudis C; Casas M; Rodriguez-Martin C; Furlanetto J; Carrasco E; Dickler MN; ; ;
    Eur J Cancer; 2019 Aug; 117():91-98. PubMed ID: 31276981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
    Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
    Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab Plays a double-edged role in Neoadjuvant Therapy for Non-metastatic Breast Cancer: A Systemic Review and Meta-Analysis.
    Chen X; Gao Y; Zhang G; Li B; Ma T; Ma Y; Wang X
    J Cancer; 2021; 12(9):2643-2653. PubMed ID: 33854624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
    de Haas S; Delmar P; Bansal AT; Moisse M; Miles DW; Leighl N; Escudier B; Van Cutsem E; Carmeliet P; Scherer SJ; Pallaud C; Lambrechts D
    Angiogenesis; 2014 Oct; 17(4):909-20. PubMed ID: 25012543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
    Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
    Tamura R; Tanaka T; Miyake K; Yoshida K; Sasaki H
    Brain Tumor Pathol; 2017 Apr; 34(2):62-77. PubMed ID: 28386777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
    Trédan O; Follana P; Moullet I; Cropet C; Trager-Maury S; Dauba J; Lavau-Denes S; Diéras V; Béal-Ardisson D; Gouttebel M; Orfeuvre H; Stefani L; Jouannaud C; Bürki F; Petit T; Guardiola E; Becuwe C; Blot E; Pujade-Lauraine E; Bachelot T
    Ann Oncol; 2016 Jun; 27(6):1020-1029. PubMed ID: 26916095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic therapy in breast cancer.
    Gampenrieder SP; Westphal T; Greil R
    Memo; 2017; 10(4):194-201. PubMed ID: 29250196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.